1. Inicio
  2. Publicaciones
  3. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Garcia-Romero, N
  • Palacin-Aliana, I
  • Madurga, R
  • Carrion-Nayarro, J
  • Esteban-Rubio, S
  • Jimenez, B
  • Collazo, A
  • Perez-Rodriguez, F
  • de Mendivil, AO
  • Fernandez-Carballal, C
  • Garcia-Duque, S
  • Diamantopoulos-Fernandez, J
  • Belda-Iniesta, C
  • Sanchez-Gomez, P
  • Calvo, E
  • Ayuso-Sacido, A

Grupos

Abstract

Background Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. Results We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo.We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Conclusions Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.

Datos de la publicación

ISSN/ISSNe:
1741-7015, 1741-7015

BMC MEDICINE  BIOMED CENTRAL LTD

Tipo:
Article
Páginas:
142-142
PubMed:
32564774
Factor de Impacto:
3,463 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 18

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • VEGFA; Angiogenesis; Bevacizumab; Glioblastoma; Neovasculogenesis

Campos de Estudio

Proyectos y Estudios Clínicos

EVALUACIÓN DEL ÍNDICE DE PROLIFERACIÓN KI-67 COMO PREDICTOR DE RECIDIVA EN MENINGIOMAS CEREBRALES GRADO I DE LA OMS. COMPARACIÓN CON LA ESCALA DE RESECCIÓN QUIRÚRGICA DE SIMPSON.

Investigador Principal: LUIS RICARDO PRAT ACÍN

2013_0041_CRC_PRAT . FUNDACION MUTUA MADRILEÑA . 2013

Cita

Compartir